Fernando Corrales-Medina
Pediatric Hematology-Oncology · Miami, FLNPI 1376701524
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 29.0% of the total. Among pediatric hematology-oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $1172.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$97K
- Octapharma USA, Inc.$60K
- Sanofi$59K
- Genentech USA, Inc.$32K
- Bayer$25K
- Shire North American Group Inc$19K
- plus $43K from 10 others
Across 94 payments — averaging $4727.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$175K
- Shire North American Group Inc$102K
- Genentech, Inc.$75K
- Boehringer Ingelheim$69K
- Daiichi Sankyo Inc.$8K
- Bioverativ Therapeutics Inc.$8K
- plus $7K from 2 others
What the payments were for
- Consulting fees$155,86046%
- Speaking & faculty fees$107,55732%
- Grants$19,8006%
- Travel & lodging$43,69413%
- Food & beverage$8,5073%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $97,259 |
| Octapharma USA, Inc. | 59 | $59,632 |
| Sanofi | 41 | $59,395 |
| Genentech USA, Inc. | 37 | $31,738 |
| Bayer | 22 | $25,135 |
| Shire North American Group Inc | 24 | $19,492 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $14,241 |
| Biomarin Pharmaceutical Inc. | 8 | $11,843 |
| CSL Behring | 8 | $8,551 |
| Pfizer | 1 | $4,400 |
| Bioverativ Therapeutics Inc. | 1 | $3,413 |
| Genentech, Inc. | 2 | $150 |
| HEMA Biologics, LLC | 1 | $140 |
| Novartis | 2 | $33 |
| Amgen | 2 | $32 |
| Duchesnay USA Incorporated | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$31,020
- NUWIQ$30,760
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$26,559
- ADVATE$20,411
- ADYNOVATE$12,967
- Jivi$10,154
- FEIBA$9,636
- OBIZUR$9,636
- Roctavian$7,693
- QFITLIA$6,786
- ALTUVIIIO$6,484
- NovoSeven$5,235
- REBINYN$5,077
- Idelvion$4,763
- Alhemo$4,536
- HYMPAVZI$4,400
- Esperoct$3,938
- HEMGENIX$3,650
How this compares
$335,473 in reported general payments places this provider in the 95th percentile of 132 pediatric hematology-oncology providers in Florida.
See all pediatric hematology-oncology providers in Florida →
Other pediatric hematology-oncology in Miami
- Guillermo DeanguloMiami$929K
- Joanna DavisMiami$411K
- Rachel KronenfeldMiami$40K
- Maggie FaderMiami$11K
- Ofelia AlvarezMiami$9K
- Julio BarredoMiami$8K
- Jorge Galvez SilvaMiami$7K
- Ossama MaherMiami$6K
- Sasha InclanMiami$5K
- Ziad KhatibMiami$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.